A randomized controlled clinical trial (NCT01934777) involving children with non-alcoholic steatohepatitis (NASH) evaluated the effects of combined supplementation with docasahexaenoic acid, choline, and vitamin E (DHA-CHO-VE) (160)
Independent labs routinely test compounded batches to confirm accuracy, purity, and compliance with USP guidelines
individual results vary) Glycemic improvement: the Lancet 2023 phase 2 trial in patients with type 2 diabetes reported meaningful HbA1c reductions alongside weight loss, supporting potential dual metabolic benefit May suit patients who have plateaued on semaglutide or tirzepatide and require a more potent metabolic intervention, following physician assessment and clinical rationale Provided with clinical-grade, COA-verified sourcing: not available as grey-market research peptide through this clinic
If the desired results are not seen after 3-6 months, or if the patient cannot tolerate the medication, discontinuation or alternative treatments may be considered
Strength training 23 times per week helps preserve lean mass